臺灣博碩士論文加值系統

本論文將說明研發藥物WRC-213和Mana-Hox對前列腺癌細胞株(PC-3)之抗癌作用機轉。
第一篇實驗主要是以一系列的實驗，說明anthracenedione類系列衍生物WRC-213引起荷爾蒙不依賴型之前列腺癌細胞株(PC-3)細胞凋亡的機轉。 WRC-213可造成PC-3細胞呈濃度與時間相關性的細胞凋亡現象， WRC-213造成DNA受損並且抑制第二型拓樸異構酶活性，細胞週期停滯在S與G2期，WRC-213引起與粒線體相關的內在性細胞凋亡途徑，造成caspase-3與-9的活化，Mcl-1裂解、Bcl-2表現量下降，而且WRC-213引起survivin表現量減少與caspase-2的活化。另外，WRC-213比臨床抗癌藥物mitoxantrone、etoposide和doxorubicin引起較低的心臟毒性與抗藥性。由實驗證明，WRC-213對治療前列腺癌是一個有潛力的拓樸異構酶作用藥物。
第二篇實驗討論β-carboline類化合物Mana-Hox引起荷爾蒙不依賴型之前列腺癌細胞株(PC-3)細胞凋亡的機轉。從流式細胞儀分析結果顯示Mana-Hox造成細胞週期停滯在G2/M期和造成凋亡細胞增加。從微管聚合實驗和西方墨點法實驗結果顯示，Mana-Hox擾亂微管的聚合並且引起DNA受損作用，Mana-Hox造成cyclin B表現量增加，Cdk1的表現量沒有變化，但是MPM-2表現量增加，而cyclin A及cyclin E 表現量下降。因此推測Mana-Hox引起細胞週期停滯在mitosis期。Mana-Hox引起與粒線體相關的內在性細胞凋亡途徑，也造成Bcl-2蛋白磷酸化，Mcl-1蛋白量減少，PARP與caspase-3活化。而且Mana-Hox在P-glycoprotein相關之抗藥性實驗中呈現較低的抗藥性。綜合上述結果，我們認為Mana-Hox在未來對前列腺癌的化學治療上是極具有潛力的化合物。

In the present studies, we elucidate the anticancer mechanism of WRC-213 and Mana-Hox in the androgen-refractory human prostate adenicarcinoma PC-3 cells.
In the first part, the research is to investigate the apoptotic mechanism of WRC-213, an anthracenedione derivative, in human prostate cancer PC-3 cells. WRC-213 induced apoptotic cell death in PC-3 cells in a concentration- and time-dependent manner. WRC-213 induced DNA damage and inhibited activity of topoisomerase II, resulting in cell cycle arrest at S and G2 phase. After the checkpoint arrest, WRC-213 induced mitochondrial-mediated intrinsic apoptotic pathway, including caspase-3/caspase-9 activation, Mcl-1 cleavage and Bcl-2 down-regulation. Survivin degradation and caspase-2 activation also contributed to WRC-213-induced apoptosis. Furthermore, the measurement of cytotoxicity in H9c2 cardiomyocytes and drug resistance in NCI/ADR-RES cells demonstrated that WRC-213 showed much lower cardiotoxicity and P-glycoprotein-related resistance than those of mitoxantrone, etoposide and doxorubicin. In conclusion, WRC-213 is a promising topoisomerase II poison for treatment of androgen-refractory human prostate adenocarcinoma.
In the second part, the research is to investigate the apoptotic mechanism of Mana-Hox, a β-carbolin derivative, in human prostate cancer PC-3 cells. The data from flow cytometric analysis showed that Mana-Hox induced the accumulation of cells at G2/M phase and hypodiploid subG1 phase of the cell cycle. Tubulin assembly and Western blotting assays indicated that Mana-Hox induced tubulin depolymerization and DNA damage. Additionally, Mana-Hox induced up-regulation of cyclin B, down-regulation of cyclin A and cyclin E protein levels, and a marked increase of MPM-2 expression, suggesting the mitotic arrest to Mana-Hox action. Mana-Hox induced the activation of mitochondria-mediated apoptosis pathways and caused phosphorylation of Bcl-2, cleavage of Mcl-1 and PARP, and activation of caspase-3. Moreover, Mana-Hox showed much lower P-glycoprotein-related resistance than taxol, vincristine, etoposide, and doxorubicin. The data suggest that Mana-Hox is a potential compound for the development of prostate cancer chemotherapy.

縮寫表……………………………………………………………………………2
中文摘要…………………………………………………………………………4
英文摘要………………………………………………………………………5
研究動機與目的…………………………………………………………………7
第一章 文獻回顧……………………………………………………………8
第二章 實驗材料及方法……………………………………………………25
第三章 WRC-213 引起前列腺癌細胞凋亡作用的機轉探討………………34
第一節 緒論……………………………………………………………...35
第二節 結果………………………………………………………………38
第三節 討論………………………………………………………………43
第四章 Mana-Hox引起前列腺癌細胞凋亡作用的機轉探討………………59
第一節 緒論……………………………………………………………….60
第二節 結果………………………………………………………………62
第三節 討論………………………………………………………………68
第五章 結論與展望……………………………………………………………82
參考文獻………………………………………………………………………84

Adachi S, Obaya AJ, Han Z, Ramos-Desimone N, Wyche JH, Sedivy JM. c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol. 2001;21(15):4929-4937.

Altieri F, Grillo C, Maceroni M, Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008; 10(5): 891-937.

Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol. 2000;10(7):261-267.

Barratt RA, Kao G, McKenna WG, Kuang J, Muschel RJ. The G2 block induced by DNA damage: a caffeine-resistant component independent of Cdc25C, MPM-2 phosphorylation, and H1 kinase activity. Cancer Res. 1998;58(12):2639-2645.

Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003; 22(56):9075-9086.

Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13(10):2849-2854. Review.

Bidwell GL 3rd, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol. 2007;73(5): 620- 631.

Borges HL, Linden R, Wang JY. DNA damage-induced cell death: lessons from the central nervous system. Cell Res. 2008;18(1):17-26. Review.

Boursereau Y, Coldham I. Synthesis and biological studies of 1-amino beta-carbolines. Bioorg Med Chem Lett. 2004;14(23):5841-5844.

Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2007;251(1):1-16.

Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98(3):523-528.
Calabrò F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007;51(1):17-26. Review.

Cann KL, Hicks GG. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol. 2007;85(6):663-674. Review.

Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23(16):2825-2837.

Chen FL, Armstrong AJ, George DJ. Cell signaling modifiers in prostate cancer. Cancer J. 2008;14(1):40-45. Review.

Chhatriwala H, Jafri N, Salgia R. A review of topoisomerase inhibition in lung cancer. Cancer Biology & Therapy. 2006; 5(12):1600-1607.

Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590-8607. Review.

Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13(24):7254-7263. Review.

Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev. 2007;33(2):203-212. Review.

Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol. 2008;9(5):378-390. Review.

Drewes G, Ebneth A, Preuss U, Mandelkow E-M, Mandlekow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89(2):297-308.

Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 2004;91(2):223-231. Review.

Estévez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004;10(10):3249-3261.

Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005;37(11):719-727. Review.

Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000;64:221-253. Review.

Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;Suppl 5:v9-v15. Review.

Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther. 2005;315(3):1403-1411.

Giles GI, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem. 2005;1(4):383-394. Review.

Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity.
J Clin Oncol. 2004;22(10):2015-2025. Review.

Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 2001; 20 (15): 1839-1851.

Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 1995;92(10):4507-4511.

Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta. 1998;1400(1-3):173-184. Review.

Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001;59(3):453-461.

Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol. 2001;39(2):121-130. Review.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204. Review.
Hendrikse NH. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des. 2000;6(16):1653-1668.

Hofmann GA, Mattern MR. Topoisomerase II in multiple drug resistance. Cytotechnology. 1993;12(1-3):137-154. Review.

Huang X, Kurose A, Tanaka T, Traganos F, Dai W, Darzynkiewicz Z. Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. Cancer Biol Ther. 2006;5(8): 959-964.

Hyzy M, Bozko P, Konopa J, Skladanowski A. Antitumour imidazoacridone c-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol. 2005;69(5):801-809.

Ismail IH, Nyström S, Nygren J, Hammarsten O. Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks. J Biol Chem. 2005;280(6):4649-4655.

Jäättelä M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999;248(1): 30-43. Review.

Jiang ZH, Zhang WJ, Rao Y, Wu JY. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc Natl Acad Sci USA. 1998;95(16): 9155-9160.

Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-265.

Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 2007;29(12):1227-1238. Review.

Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006;281(30):21256-21265.

Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control. 2001;8(6):487-495. Review.

Kremer CL, Schmelz M, Cress AE. Integrin-dependent amplification of the G2 arrest induced by ionizing radiation. Prostate. 2006;66(1):88-96.

Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99-163. Review.

Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis. 2005;10(5):1111-1120.

Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003;15(6):691-699. Review.

Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther. 2003;99(2):167-181. Review.

Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18(6):616-622.

Léonce S, Perez V, Casabianca-Pignede MR, Anstett M, Bisagni E, Pierré A, Atassi G. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs. 1996;14(2):169-180.

Lim LS, Sherin K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008; 34(2):164-170. Review.

Ling YH, Tornos C, Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem. 1998;273(30):18984-18991.

Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 2003;22(53):8568-8580. Review.

Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy. 1993;13(2):88-109.

Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997;8(9):811-822. Review

Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994;31(1):1-13.

Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003;29(3):171-187. Review.

Martinez V, Mir O, Dômont J, Bouscary D, Goldwasser F. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. Anticancer Drugs. 2007;18(2):233-235.

McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res. 2007;623(1-2):83-97.

McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96-132.

McGrath JL. Dynein motility: four heads are better than two. Curr Biol. 2005;15(23): R970-972.
Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol. 2005;37(2): 267- 271. Review.

Mikhailov A, Shinohara M, Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol. 2004;166(4):517-526.

Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer. 2007;120(1):160-169.

Moinet-Hedin V, Tabka T, Poulain L, Godard T, Lechevrel M, Saturnino C, Lancelot JC, Le Talaer JY, Gauduchon P. Biological properties of 5,11-dimethyl-6H-pyrido [3,2-b]carbazoles: a new class of potent antitumour drugs. Anticancer Drug Des. 2000;15(2):109-118.

Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007;252(1):9-18. Review.

Morohashi K, Yoshino A, Yoshimori A, Saito S, Tanuma S, Sakaguchi K, Sugawara F. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP. Biochem Pharmacol. 2005;70:37–46.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo. Cancer Sci. 2003;94(1):119-124.

Nguyen H-L, Gruber D, McGraw T, Sheetz MP, Bulinski JC. Stabilization and functional modulation of microtubules by microtubuleassociated protein 4. Biol Bull. 1998;194(3):354-357.

Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis. 2006;21 (1):3-9.

Oliver L, Vallette FM. The role of caspases in cell death and differentiation. Drug Resist Updat. 2005;8(3):163-170. Review.

Opferman JT. Apoptosis in the development of the immune system. Cell Death Differ. 2008;15(2):234-242. Review.

Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47):7280-7295.

Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Research. 2004;64(15):5036-5043.

Perez-Stable C. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006;231(1):49-64.

Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005;23(3):264-273.

Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther. 2007;321(3): 1109-1117.

Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM. S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol. 2005;56(5):447-454.

Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999;59(4): 862-867.

Ray S, Shyam S, Fraizer GC, Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther. 2007;6(4):1368-1378.

Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402-412. Review.

Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12(9):440-450. Review.

Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408-9421. Review

Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents. 2005;5(3):251-265.

Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf. 2005;4(2): 219-234. Review.

Shiah HS, Lee WS, Juang SH, Hong PC, Lung CC, Chang CJ, Chou KM, Chang JY. Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. Biochem Pharmacol. 2007;73(5):610-619.

Silverman JA. Multidrug-resistance transporters. Pharm Biotechnol. 1999;12:353-386.

Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs. 1995;49(1):11-19. Review.

Skjøth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol. 2006 ;28(1):217-229.

Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 2003;24(3):139-145. Review.

Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R. Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J Biol Chem. 2001;276(11):8029-8036.

Tanaka T, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle. 2006;5(17):1940-1945.

Tanaka T, Huang X, Halicka HD, Zhao H, Traganos F, Albino AP, Dai W, Darzynkiewicz Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A. 2007;71(9):648-661.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.

Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, Zajchowski DA. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia. 2007;9(7):601-613.

Toso C, Lindley C. Vinorelbine: a novel vinca alkaloid. Am J Health Syst Pharm. 1995 ;52(12):1287-1304.

Tu LC, Chou CK, Chen CY, Chang YT, Shen YC, Yeh SF. Characterization of the cytotoxic mechanism of Mana-Hox, an analog of manzamine alkaloids. Biochim Biophys Acta. 2004;1672(3):148-156.

Tu LC, Chen CS, Hsiao IC, Chern JW, Lin CH, Shen YC, Yeh SF. The beta-carboline analog Mana-Hox causes mitotic aberration by interacting with DNA. Chem Biol. 2005;12(12):1317-1324.

Uhm JE, Lim HY, Kim WS, Choi HY, Lee HM, Park BB, Park K, Kang WK. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia. 2007;9(1):18-22.

Urist, M. Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18(24):3041-3054.

van den Heuvel S. Cell-cycle regulation. WormBook. 2005;1-16. Review.

Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131-149.

Wang Y, Wiltshire T, Senft J, Reed E, Wang W. Irofulven induces replication- dependent CHK2 activation related to p53 status. Biochem Pharmacol. 2007;73(4): 469-480.

Watanabe K, Kubota M, Hamahata K, Lin Y, Usami I. Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-kappab activation. Biochem Pharmacol. 2000;60(6):823-830.

Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate. 1997;30(1):58-64. Review.

Yang F, Chen Y, Duan W, Zhang C, Zhu H, Ding J. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer. 2006;119(5):1184-1193.

Yazlovitskaya EM, Persons DL. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res. 2003;23(3B):2275-2279.

Zijlstra JG, de Jong S, de Vries EG, Mulder NH. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother. 1990;7(1):11-18. Review.